These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19888985)

  • 1. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.
    Petrylak DP; Tangen CM; Van Veldhuizen PJ; Goodwin JW; Twardowski PW; Atkins JN; Kakhil SR; Lange MK; Mansukhani M; Crawford ED
    BJU Int; 2010 Feb; 105(3):317-21. PubMed ID: 19888985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
    J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
    Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
    Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
    Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
    J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
    Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
    Culine S; Sellam Z; Bouaita L; Assaf E; Delbaldo C; Verlinde-Carvalho M; Pouessel D
    Anticancer Res; 2012 Sep; 32(9):3949-52. PubMed ID: 22993342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
    Wülfing C; Machiels JP; Richel DJ; Grimm MO; Treiber U; De Groot MR; Beuzeboc P; Parikh R; Pétavy F; El-Hariry IA
    Cancer; 2009 Jul; 115(13):2881-90. PubMed ID: 19399906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
    Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
    West HL; Franklin WA; McCoy J; Gumerlock PH; Vance R; Lau DH; Chansky K; Crowley JJ; Gandara DR
    J Clin Oncol; 2006 Apr; 24(12):1807-13. PubMed ID: 16622257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study.
    Abdel-Malek R; Shohdy KS; Abbas N; Ismail M; Hamada E; Abdel-Kader Y
    Curr Drug Saf; 2019; 14(1):31-36. PubMed ID: 30277164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin].
    Ribrag V; Ghnassia M; Théodore C; Ghosn M; Piot G; Beurton D; Cukier J; Droz JP
    J Urol (Paris); 1990; 96(7):373-4. PubMed ID: 2290037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
    Pond GR; Agarwal N; Bellmunt J; Choueiri TK; Qu A; Fougeray R; Vaughn D; James ND; Salhi Y; Albers P; Niegisch G; Galsky MD; Wong YN; Ko YJ; Stadler WM; O'Donnell PH; Sridhar SS; Vogelzang NJ; Necchi A; Di Lorenzo G; Sternberg CN; Mehta A; Sonpavde G
    BJU Int; 2014 May; 113(5b):E137-43. PubMed ID: 24219029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.